Since our establishment, we have built a highly capable organization that combines strategic leadership, scientific depth, and operational excellence. Supported by our end-to-end innovation capability, we have achieved rapid and efficient advancement of our ADC pipeline, with multiple candidates progressing from project initiation to clinical stage within a short period. Several potentially first-in-class programs, including AMT-116, AMT-253 and AMT-676, have entered multinational clinical trials, demonstrating our strong clinical strategy design and execution capabilities.
These achievements are driven by the strategic vision of our core management team, whose collective expertise spans target discovery, ADC molecular design, clinical operations, and global regulatory strategy. Their complementary experience across research innovation, clinical execution, and corporate management has enabled the Company to establish a clear and sustainable development roadmap, ensuring that each stage of advancement aligns with both clinical needs and international standards.
Management Team
Dr. Meng, Ph.D., our founder and chief executive officer, has over 30 years of scientific and managerial experience in the biopharmaceutical industry, with deep expertise in antibody discovery, drug development and translational research. Prior to joining our Company, he served senior scientific and leadership positions at multiple biotechnology companies. He holds a doctorate degree in philosophy from New York University.
Ms. Yanfang Tang, our chief operating officer, has extensive experience in R&D operations, organizational management and corporate administration within the biopharmaceutical industry. Prior to joining our Company, she held senior management roles at several biotechnology companies, where she oversaw R&D operations and corporate administration functions. Ms. Tang holds an associate degree in medicine from Fudan University and graduated from Shanghai Jiao Tong University with a major in medicine management.
Dr. Shu Hui Liu, Ph.D., our chief scientific officer, brings more than 20 years of experience across biotechnology and multinational pharmaceutical companies, including director of the tumor biology group at Pfizer. She has extensive expertise in target biology, translational research and drug discovery, and holds a doctorate degree in science from National Tsing-Hua University.
In addition to the leadership team, we are supported by an experienced R&D team. Our R&D team possesses deep expertise across drug discovery and early research, translational and preclinical development, and clinical operations.
Together, our leadership and R&D teams form an integrated, execution-driven organization that combines global biopharmaceutical expertise with scientific excellence. This synergy ensures that our innovation pipeline is advanced with rigorous scientific discipline, efficient execution, and a shared vision of delivering transformative therapies to patients worldwide.